Erik Tillman
Company: Akero Therapeutics
Job title: Principal Scientist
Seminars:
What the Latest Advances in Our Understanding of NASH Pathogenesis & Pathophysiology Can Tell Us About Past & Future Therapeutic Approaches 1:30 pm
• Outlining our understanding of the pathogenesis and pathophysiology of NAFLD and NASH, from the molecular to the whole-body level • Hearing what clinical trials in NASH have taught us about different therapeutic targets and pathways, and why “what you measure” matters • Integrating the latest basic, translational, and clinical research to improve NASH therapeutic…Read more
day: Day 2 Stream 1 PM